Can a Two-Drug antiviral combo boost survival in liver cancer patients?
NCT ID NCT07253220
First seen Jan 04, 2026 · Last updated Jun 13, 2026 · Updated 24 times
Summary
This study looks at 120 adults with advanced hepatitis B-related liver cancer who are also getting immunotherapy. It compares taking one antiviral drug (TAF) alone versus taking two drugs (ETV plus TAF) to see which helps people live longer. The goal is to find the best way to control the hepatitis B virus during cancer treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.